Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium

Simple item page
dc.contributor.authorVázquez, Gustavo
dc.contributor.authorBahji, Anees
dc.contributor.authorUndurraga, Juan
dc.contributor.authorTondo, Leonardo
dc.contributor.authorBaldessarini, Ross
dc.date.accessioned2022-03-28T13:49:07Z
dc.date.available2022-03-28T13:49:07Z
dc.date.issued2021
dc.description.abstractAbstract Background: Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD include increasing antidepressant dose, combining antidepressants, adding adjunctive agents, or using nonpharmacological treatments. Their relative efficacy and tolerability remain inadequately tested. In particular, the value and safety of increasingly employed second-generation antipsychotics (SGAs) and new esketamine, compared to lithium as antidepressant adjuncts remain unclear. Methods: We reviewed randomized, placebo-controlled trials and used random-effects meta-analysis to compare odds ratio (OR) versus placebo, as well as numbers-needed-to-treat (NNT) and to-harm (NNH), for adding SGAs, esketamine, or lithium to antidepressants for major depressive episodes. Results: Analyses involved 49 drug-placebo pairs. By NNT, SGAs were more effective than placebo (NNT=11 [CI: 9–15]); esketamine (7 [5–10]) and lithium (5 [4–10]) were even more effective. Individually, aripiprazole, olanzapine+fluoxetine, risperidone, and ziprasidone all were more effective (all NNT<10) than quetiapine (NNT=13), brexpiprazole (16), or cariprazine (16), with overlapping NNT CIs. Risk of adverse effects, as NNH for most- frequently reported effects, among SGAs versus placebo was 5 [4–6] overall, and highest with quetiapine (NNH=3), lowest with brexpiprazole (19), 5 (4–6) for esketamine, and 9 (5–106) with lithium. The risk/benefit ratio (NNH/NNT) was 1.80 (1.25–10.60) for lithium and much less favorable for esketamine (0.71 [0.60–0.80]) or SGAs (0.45 [0.17–0.77]). Conclusions: Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episodes, but lithium was somewhat more effective and better tolerated. Limitations: Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized.es
dc.description.versionVersión publicadaes
dc.identifier.citationVázquez, Gustavo H., et al. “Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.” Journal of Psychopharmacology, vol. 35, no. 8, Aug. 2021, pp. 890–900, doi:10.1177/02698811211013579.es
dc.identifier.urihttps://doi.org/10.1177/02698811211013579es
dc.identifier.urihttp://hdl.handle.net/11447/5815
dc.language.isoenes
dc.subjectAntidepressantses
dc.subjectAntipsychoticses
dc.subjectCombinationes
dc.subjectDepressiones
dc.subjectEfficacyes
dc.subjectEsketaminees
dc.subjectLithiumes
dc.titleEfficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithiumes
dc.typeArticlees
dcterms.sourcePsychopharmes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy and Tolerability of Combination.pdf
Size:
571.27 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services